research use only

Paroxetine HCl Serotonin Transporter inhibitor

Cat.No.S3005

Paroxetine HCl (BRL-29060A, FG-7051) is an antidepressant drug of the SSRI type.
Jump to

Quality Control

Batch: S300502 DMSO]73 mg/mL]false]Ethanol]35 mg/mL]false]Water]1 mg/mL]false Purity: 99.95%
99.95

Solubility

In vitro
Batch:

DMSO : 73 mg/mL (199.54 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 35 mg/mL

Water : 1 mg/mL

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 365.83 Formula

C19H20FNO3.HCl

Storage (From the date of receipt)
CAS No. 78246-49-8 Download SDF Storage of Stock Solutions

Synonyms BRL-29060A, FG-7051 SMILES C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4.Cl

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC50/Ki
AChR
5-HT
In vitro
Paroxetine apparently exerts their antidepressant activity by increasing the concentration of 5-HT in the extracellular compartment, thereby enhancing serotoninergic neurotransmission. Paroxetine (1-300 μM) results in a concentration-dependent reduction in the firing rate of DRN serotoninergic neurons with IC50 values of 1.4 μM in the ACSF superfusing brain stem slices. Paroxetine is a highly potent inhibitor of desipramine hydroxylation, the inhibition constant (Ki) value of 2.0 mM indicated greater inhibiting potency than fluoxetine or norfluoxetine. Paroxetine is shown to be a potent (Ki = 1.1 nM) and specific inhibitor of [3H]-5-hydroxytryptamine (5-HT) uptake into rat cortical and hypothalamic synaptosomes in vitro. Paroxetine demonstrates weak affinity for muscarinic receptors (Ki = 89 nM) but is at least 15 fold weaker than amitriptyline (Ki = 5.1 nM). Paroxetine inactivates CYP2D6 via the formation of a metabolite intermediate complex.
In vivo
Paroxetine produces a dose-related inhibition of [3H]-5-HT uptake (ED50 = 1.9 mg/kg) into rat hypothalamic synaptosomes ex vivo with little effect on [3H]-l-noradrenaline (NA) uptake (ED50 greater than 30 mg/kg). Paroxetine (ED50 1-3 mg/kg PO) prevents the 5-HT depleting effect of p-chloroamphetamine (PCA) in rat brain, demonstrating 5-HT uptake blockade in vivo.
References
  • [4] https://pubmed.ncbi.nlm.nih.gov/12584155/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-09-02)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07070232 RECRUITING
Advanced Solid Tumor
BioNTech SE
2025-08-12 PHASE1; PHASE2
NCT07318181 RECRUITING
Post Traumatic Stress Disorder; Post Traumatic Stress Disorder PTSD; Post-Traumatic Stress Disorder, PTSD
University of Luxembourg
2026-01-01
NCT07715669 RECRUITING
Preeclampsia; Endothelial Function
Anna Stanhewicz, PhD
2026-08-30 EARLY_PHASE1
NCT07025590 RECRUITING
Cardiovascular Diseases (CVD); Depression Anxiety Disorder
Guangdong Provincial People's Hospital
2025-04-22
NCT06796946 NOT_YET_RECRUITING
Deprescription; Antidepressants
University of Huelva
2026-06 EARLY_PHASE1
NCT06799169 ACTIVE_NOT_RECRUITING
Tinnitus
University of California, Irvine
2025-06-01 PHASE4

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.